Emerging therapies in the medical treatment of uterine fibroids

被引：0
作者：
Goitia, Mikel [1 ]
Estadella, Josep [2 ]
机构：
[1] Hosp Univ Cruces, Serv Ginecol & Obstet, Baracaldo, Bizkaia, Spain
[2] Hosp De La Santa Creu & St Pau, Serv Ginecol, Barcelona, Spain
来源：
MEDICINA CLINICA | 2023年 / 161卷
关键词：
PROGESTERONE-RECEPTOR MODULATORS; ADD-BACK THERAPY; ULIPRISTAL ACETATE; ANTAGONIST LINZAGOLIX; WOMEN; EFFICACY; SAFETY; ELAGOLIX; PLACEBO; VILAPRISAN;
D O I：
10.1016/j.medcli.2023.06.034
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S32 / S37
页数：6
相关论文
共 42 条
[41]   Epidemiology of uterine fibroids: a systematic review [J].
Stewart, E. A. ;
Cookson, C. L. ;
Gandolfo, R. A. ;
Schulze-Rath, R. .
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2017, 124 (10) :1501-1512
[42]   Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide Gonadotropin-Releasing Hormone Antagonist Elagolix [J].
Struthers, R. Scott ;
Nicholls, Andrew J. ;
Grundy, John ;
Chen, Takung ;
Jimenez, Roland ;
Yen, Samuel S. C. ;
Bozigian, Haig P. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (02) :545-551
12345